Eliem Therapeutics (ELYM) Institutional Ownership → Write this ticker symbol down… (From StocksToTrade) (Ad) Free ELYM Stock Alerts $8.88 +0.40 (+4.72%) (As of 06/7/2024 08:51 PM ET) Add Compare Share Share OwnershipStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Eliem Therapeutics (NASDAQ:ELYM)CurrentInstitutional OwnershipPercentage69.76%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$2.07MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$1.19M Get ELYM Insider Trade Alerts Want to know when executives and insiders are buying or selling Eliem Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ELYM Institutional Buying and Selling by Quarter Ad StocksToTradeWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.Discover the #1 company leading this revolution Eliem Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails4/23/2024 BML Capital Management LLC2,193,742$6.01M4.0%+0.6%7.914% 1/30/2024 BML Capital Management LLC2,180,000$5.89M4.4%+12.5%7.907% 1/26/2024 Cerity Partners LLC13,821$37K0.0%N/A0.050% 11/13/2023 Silverarc Capital Management LLC121,110$319K0.1%-75.5%0.447% 10/23/2023 BML Capital Management LLC1,938,263$5.10M4.7%+22.4%7.155% 8/15/2023 Silverarc Capital Management LLC494,089$1.38M0.4%+1.7%1.830% Get the Latest News and Ratings for ELYM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/14/2023 Driehaus Capital Management LLC810,593$2.27M0.0%+20.3%3.003% 7/24/2023 BML Capital Management LLC1,583,170$4.43M4.0%-4.5%5.866% 4/14/2023 BML Capital Management LLC1,658,170$4.81M4.2%-9.1%6.148% 2/14/2023 Driehaus Capital Management LLC551,942$2.03M0.0%+58.3%2.077% 2/13/2023 BML Capital Management LLC1,825,134$6.70M6.4%N/A6.869% 2/1/2023 Bank of Montreal Can25,244$93K0.0%N/A0.095% 11/8/2022 Atom Investors LP67,074$217K0.1%+154.9%0.252% 10/28/2022 Silverarc Capital Management LLC402,088$1.30M0.4%-43.6%1.513% 8/16/2022 Parkwood LLC67,202$67K0.2%+63.4%0.253% 7/25/2022 Silverarc Capital Management LLC713,009$2.15M0.7%+707.7%2.684% 5/12/2022 Monashee Investment Management LLC227,201$1.91M0.6%-24.3%0.855% 5/9/2022 Qube Research & Technologies Ltd15,874$133K0.0%N/A0.060% 2/19/2022 Woodline Partners LP373,368$3.91M0.1%-3.6%1.406% 2/15/2022 Samlyn Capital LLC1,703,546$17.82M0.2%+1.3%6.417% 2/11/2022 Parkwood LLC30,609$320K0.1%N/A0.115% 2/7/2022 Monashee Investment Management LLC300,000$3.14M0.8%-1.7%1.130% 2/2/2022 New York State Common Retirement Fund3,359$35K0.0%N/A0.013% 1/28/2022 Allspring Global Investments Holdings LLC2,880$30K0.0%N/A0.011% 12/29/2021 Hudson Bay Capital Management LP100,000$1.80M0.0%N/A0.377% 11/15/2021 Tudor Investment Corp Et Al287,294$5.17M0.0%N/A1.082% 11/15/2021 RA Capital Management L.P.13,150,849$236.45M3.3%N/A49.536% 11/15/2021 Caas Capital Management LP75,000$1.35M0.0%N/A0.283% 11/12/2021 Geode Capital Management LLC76,904$1.38M0.0%N/A0.290% 11/10/2021 Goldman Sachs Group Inc.165,952$2.98M0.0%N/A0.625% 11/9/2021 BlackRock Inc.332,126$5.97M0.0%N/A1.251% 11/9/2021 Monashee Investment Management LLC305,233$5.49M1.0%N/A1.150% 11/4/2021 Deutsche Bank AG4,063$73K0.0%N/A0.015% (Data available from 1/1/2016 forward) ELYM Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ELYM shares? During the previous two years, the following institutional investors and hedge funds held shares of Eliem Therapeutics shares: BML Capital Management LLC ($6.01M), Driehaus Capital Management LLC ($2.27M), Silverarc Capital Management LLC ($319K), Atom Investors LP ($217K), Bank of Montreal Can ($93K), and Parkwood LLC ($67K), and Cerity Partners LLC ($37K).Learn more on ELYM's institutional investors. What percentage of Eliem Therapeutics stock is owned by institutional investors? 69.76% of Eliem Therapeutics stock is owned by institutional investors. Learn more on ELYM's institutional investor holdings. Which institutional investors have been buying Eliem Therapeutics stock? The following institutional investors have purchased Eliem Therapeutics stock in the last 24 months: BML Capital Management LLC ($2.44M), Silverarc Capital Management LLC ($632.86K), Driehaus Capital Management LLC ($340.28K), Atom Investors LP ($40.77K), Parkwood LLC ($26.07K), Bank of Montreal Can ($25.24K), and Cerity Partners LLC ($13.82K). How much institutional buying is happening at Eliem Therapeutics? Institutional investors have bought a total of 3,514,749 shares in the last 24 months. This purchase volume represents approximately $11.70M in transactions. Which Eliem Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Eliem Therapeutics stock in the last 24 months: Silverarc Capital Management LLC ($683.90K), and BML Capital Management LLC ($241.96K). How much institutional selling is happening at Eliem Therapeutics? Institutional investors have sold a total of 925,864 shares in the last 24 months. This volume of shares sold represents approximately $2.68M in transactions. Related Companies: XBiotech Major Shareholders Compugen Major Shareholders Cue Biopharma Major Shareholders Marinus Pharmaceuticals Major Shareholders Biora Therapeutics Major Shareholders MEI Pharma Major Shareholders COMPASS Pathways Major Shareholders Altimmune Major Shareholders Immunome Major Shareholders Ocular Therapeutix Major Shareholders This page (NASDAQ:ELYM) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.